How big is Fate Therapeutics, Inc.?

As of Jun 18, Fate Therapeutics, Inc. has a market capitalization of 137.56 million, classifying it as a Micro Cap company, with net sales of 13.33 million and a net profit of -175.88 million over the latest four quarters. The company reported shareholder's funds of 318.73 million and total assets of 440.69 million as of Dec 24.

Market Cap: As of Jun 18, Fate Therapeutics, Inc. has a market capitalization of 137.56 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Fate Therapeutics, Inc. reported net sales of 13.33 million and a net profit of -175.88 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 318.73 million and total assets of 440.69 million.

What does Fate Therapeutics, Inc. do?

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune disorders. As of March 2025, it has a market cap of $137.56 million, with net sales of $2 million and a net loss of $38 million.

Overview: <BR>Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -38 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 137.56 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.81 <BR>Return on Equity: -56.74% <BR>Price to Book: 0.48<BR><BR>Contact Details: <BR>Address: 3535 General Atomics Ct Ste 200, SAN DIEGO CA: 92121-1140 <BR>Tel: ['1 858 8751803', '1 212 3621200'] <BR>Fax: 1 302 6365454 <BR>Website: http://fatetherapeutics.com/

Should I buy, sell or hold Fate Therapeutics, Inc.?

Who are in the management team of Fate Therapeutics, Inc.?

As of March 2022, the management team of Fate Therapeutics, Inc. includes Dr. William Rastetter (Independent Chairman), Mr. John Wolchko (CEO), and several independent directors, including Dr. John Mendlein and Dr. Shefali Agarwal.

As of March 2022, the management team of Fate Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. William Rastetter, Independent Chairman of the Board<BR>- Mr. John Wolchko, President, Chief Executive Officer, Director<BR>- Dr. John Mendlein, Independent Vice Chairman of the Board<BR>- Dr. Shefali Agarwal, Director<BR>- Dr. Robert Hershberg, Director<BR>- Mr. Timothy Coughlin, Independent Director<BR>- Dr. Robert Epstein, Independent Director<BR>- Dr. Karin Jooss, Independent Director<BR><BR>In summary, as of March 2022, the management team consists of a mix of independent directors and key executives, including the CEO and chairpersons.

Is Fate Therapeutics, Inc. technically bullish or bearish?

As of August 25, 2025, Fate Therapeutics, Inc. has shifted to a bearish trend with weak strength indicators, showing a 1-year return of -74.23% and a 5-year return of -97.45% compared to the S&P 500's positive performance.

As of 25 August 2025, the technical trend for Fate Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages being bearish and the KST showing bearish signals on both weekly and monthly time frames. The Bollinger Bands also reflect a bearish outlook on the monthly timeframe. Multi-period returns show significant underperformance compared to the S&P 500, with a 1-year return of -74.23% versus 17.14% for the benchmark, and a staggering 5-year return of -97.45% compared to 96.61% for the S&P 500.